Clinical trial
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis…
NCT00096603 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096603 |
|---|---|
| Title | A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g |
| Official title | An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Raptiva (efalizumab) |
| Enrollment | 450 |
| Start date | Oct 1, 2002 |
| Completion | Jul 1, 2004 |
| First posted | Nov 15, 2004 |
| Last update posted | Mar 20, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: